Pfizer to Pay Billions for Alleged Off-Label Promotions

Drug Industry Daily
A A
Pfizer had a $2.3 billion expense in its fourth quarter for settling allegations that it promoted off-label use of its Cox-2 inhibitor pain drug Bextra — just a few months after it recorded a $900 million cost related to Cox-2 product liability litigation.

To View This Article:

Login

Subscribe To Drug Industry Daily